Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3

• DOI: 10.3389/fgene.2023.1045061
• Publication Date: 2023-03-22T05:43:50Z
• Authors: Yinteng Wu; Bo Zhang; Juan Nong; Raquel Alarcòn Ro...; Wenliang Guo; Ying Liu; Shijian Zhao; Ruqiong Wei
• Keywords: collagen; the tumor microenvironment (TME); epithelial-mesenchymal transition (EMT); prolyl 4-hydroxylase subunit alpha 3 (P4HA3); pan-cancer; Genetics; immunotherapy; QH426-470; 3. Good health

Purpose: Prolyl 4-hydroxylase subunit alpha 3 (P4HA3) is implicated in several cancers' development. However, P4HA3 has not been reported other cancers, and the exact mechanism of action currently unknown. Materials methods: First, expression profile was analyzed using a combination University California Santa Cruz (UCSC) database, Cancer Cell Line Encyclopedia (CCLE) Genotype-Tissue Expression (GTEx) database. UniCox Kaplan-Meier were used to analyze predictive value P4HA3. The clinical staging, immune subtypes, Molecular subtypes. Secondly, correlation with immunomodulatory genes, checkpoint RNA modification cell infiltration, cancer-related functional status, tumor stemness index, DNA mismatch repair (MMR) genes Methyltransferase examined. role methylation, copy number variation (CNV), mutational burden (TMB), microsatellite instability (MSI) also analyzed. In addition, gene set enrichment analysis (GSEA) explore potential mechanisms pan-cancer. Finally, P4HA3-related drugs searched CellMiner, Genomics Drug Sensitivity (GDSC), Therapeutics Response Portal (CTRP) databases. Results: significantly overexpressed most cancers associated poor prognosis. strongly cancer stage, molecular regulatory modifier MMR Gene, Methyltransferase, CNV, TMB, MSI are closely related. Available revealed that epithelial-mesenchymal transition immune-related pathways. There 20 Conclusion: human pan-cancer, patient prognosis multiple cells may be novel immunotherapeutic target. It act on progression through (EMT) pathway.